Imipenem/relebactam
Imipenem/relebactam is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Infections caused by susceptible Gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o; approval of these indications is based on limited clinical safety and efficacy data.
- Treatment of complicated urinary tract infections, including pyelonephritis (cUTI)
- Complicated intra-abdominal infections (cIAI)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- MDR infections including bacteremia, pneumonia, osteomyelitis
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Infections caused by susceptible Gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o; approval of these indications is based on limited clinical safety and efficacy data.
- Treatment of complicated urinary tract infections, including pyelonephritis (cUTI)
- Complicated intra-abdominal infections (cIAI)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- MDR infections including bacteremia, pneumonia, osteomyelitis
There's more to see -- the rest of this entry is available only to subscribers.
© 2000–2021 Unbound Medicine, Inc. All rights reserved